Status:
COMPLETED
C5a Receptor Expression - COVID-19 (C5-COV)
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Collaborating Sponsors:
Innate Pharma
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The pathophysiology of ARDS is linked to an uncontrolled inflammatory response at the level of alveolo-capillary membrane, mediated by neutrophils and mononuclear cells. The complement system and anap...
Detailed Description
The pathophysiology of ARDS is linked to an uncontrolled inflammatory response at the level of alveolo-capillary membrane, mediated by neutrophils and mononuclear cells. The complement system and anap...
Eligibility Criteria
Inclusion
- For patients in resuscitation unit with ARDS linked to COVID-19:
- Patient under invasive mechanical ventilation
- PaO2 / FiO2 \<300
- PCR SARS-CoV-2 positive in a pharyngeal or respiratory sample
- For control patients with COVID-19 without ARDS
- Oxygen flow always less than 5 L / min
- PCR SARS-CoV-2 positive in a pharyngeal or respiratory sample
- No passage in resuscitation unit
- Favorable evolution
Exclusion
- Minors
- Patient deprived of liberty
- Patient's refusal to participate at study
- Patient for whom therapeutic limitation measures such as non-admission to intensive care have been issued
- Medullar aplasia
Key Trial Info
Start Date :
March 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 9 2023
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT04369820
Start Date
March 31 2020
End Date
August 9 2023
Last Update
August 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique Hôpitaux de Marseille
Marseille, France, 13354